SearchDictionaryMobileLogin

Eric J Small Selected Research

Hormones

09/2008Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer.
09/2008A Phase II Study of Estramustine, Docetaxel, and Exisulind in Patients with Hormone- Refractory Prostate Cancer: Results of Cancer and Leukemia Group B Trial 90004.
02/2008A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
10/2007A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
10/2007Management of hormone refractory prostate cancer.
10/2007Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development.
10/2007Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
08/2007Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
07/2007Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.
06/2007A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
03/2007A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
03/2007Intermittent chemotherapy for metastatic hormone refractory prostate cancer.
03/2007Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer.
07/2006Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies.
07/2006A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
07/2006Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
05/2006Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
03/2006Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
08/2005Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
04/2005Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer.
03/2005The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
11/2004Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
09/2004Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
08/2004Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
02/2004Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer.
12/2003A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
04/2003Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.
10/2002Hormone-refractory Prostate Cancer.
06/2002Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer.

Articles by Research Topic

Disease

65Prostatic Neoplasms (Prostate Cancer)
09/2008 - 02/2002
19Neoplasms (Cancer)
09/2008 - 06/2002
15Leukemia
09/2008 - 08/2002
8Renal Cell Carcinoma (Grawitz Tumor)
09/2008 - 04/2004
3Carcinoma (Carcinomatosis)
01/2008 - 12/2003
2Pain (Aches)
05/2008 - 12/2003
2Transitional Cell Carcinoma
10/2005 - 05/2005
2Small Cell Carcinoma
06/2003 - 09/2002
1Kidney Neoplasms (Kidney Cancer)
09/2006
1Urinary Bladder Neoplasms (Bladder Cancer)
07/2005
1Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
04/2005
1Disease Progression
07/2004

Drug/Important Bio-Agent (IBA)

29HormonesIBA
09/2008 - 06/2002
7EstramustineFDA Link
09/2008 - 12/2003
6docetaxel (Taxotere)FDA Link
09/2008 - 12/2003
6sipuleucel-T (APC8015)IBA
04/2008 - 06/2005
6Prostate-Specific Antigen (Semenogelase)IBA
02/2008 - 06/2002
5Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA
09/2008 - 01/2003
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2008 - 04/2004
4gefitinib (Iressa)FDA Link
01/2008 - 09/2002
4Ketoconazole (Nizoral)FDA LinkGeneric
12/2007 - 08/2002
3gemcitabineFDA Link
01/2008 - 02/2005
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2007 - 09/2002
3Carboplatin (JM8)FDA LinkGeneric
10/2005 - 12/2003
2Cisplatin (Platino)FDA LinkGeneric
01/2008 - 10/2005
2ixabepilone (BMS 247550)FDA Link
08/2007 - 03/2005
2Mitoxantrone (Novantrone)FDA LinkGeneric
08/2007 - 10/2004
2Prednisone (Sone)FDA LinkGeneric
08/2007 - 10/2004
2imatinib (Gleevec)FDA Link
06/2007 - 10/2006
2capecitabine (Xeloda)FDA Link
09/2006 - 02/2005
2prostatic acid phosphataseIBA
09/2006 - 07/2006
2bevacizumabFDA Link
07/2006 - 04/2004
2Interferon-alpha (Interferon Alfa)FDA Link
02/2006 - 04/2004
2Suramin (Suramin Sodium)IBA
11/2004 - 08/2002
2herbal preparation PC-SPESIBA
09/2004 - 02/2002
2Epidermal Growth Factor Receptor (EGF Receptor)IBA
06/2003 - 09/2002
1sulindac sulfone (exisulind)IBA
09/2008
1Testosterone (Sustanon)FDA LinkGeneric
03/2008
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
10/2007
14- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)IBA
10/2007
1AntigensIBA
08/2007
1Insulin (Novolin)FDA Link
03/2007
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
03/2006
1celecoxib (Celebrex)FDA Link
02/2006
1Paclitaxel (Taxol)FDA LinkGeneric
10/2005
1Estrogens (Estrogen)FDA Link
09/2005
1Chromogranin AIBA
08/2005
1tipifarnib (R115777)IBA
05/2005
1TransferasesIBA
05/2005
1Etoposide (VP 16)FDA LinkGeneric
04/2005
1Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric
04/2005
1epothilone B (EPO906)IBA
03/2005
1Interleukin-6 (Interleukin 6)IBA
03/2005
1Diethylstilbestrol (Stilbestrol)FDA Link
09/2004
17-hydroxystaurosporine (UCN 01)IBA
07/2004
1Protein Kinase CIBA
07/2004
1flt3 ligand protein (flt3 ligand)IBA
02/2004
1Granulocyte Colony-Stimulating Factor (G-CSF)IBA
12/2003
1pamidronate (APD)FDA LinkGeneric
12/2003
1Androgen Receptors (Androgen Receptor)IBA
07/2003
1Hydrocortisone (Cortisol)FDA LinkGeneric
08/2002
1Doxorubicin (Adriamycin)FDA LinkGeneric
06/2002

Therapy/Procedure

9Immunotherapy
09/2008 - 06/2003
6Drug Therapy (Chemotherapy)
08/2007 - 09/2004
5Castration
05/2008 - 10/2002
3Prostatectomy (Retropubic Prostatectomy)
02/2007 - 08/2002
1Stem Cell Transplantation
07/2006
1Therapeutics
11/2005
1Complementary Therapies (Alternative Medicine)
12/2002